The condition shown in the picture above represents myasthenia gravis.
- Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies form against acetylcholine nicotinic postsynaptic receptors at the neuromuscular junction of skeletal muscles.
- The usual initial complaint is a specific muscle weakness rather than generalized weakness
- Extraocular muscle weakness or ptosis is present initially in 50% of patients and occurs during the course of illness in 90%.
- Weakness tends to spread from the ocular to facial to bulbar muscles and then to truncal and limb muscles.
Therapy for MG includes the following:
Anticholinesterase (AchE) inhibitors
- Initial treatment for mild MG
- Pyridostigmine is used for maintenance therapy .
- Neostigmine is generally used only when pyridostigmine is unavailable
- Immunomodulating agents
- Intravenous immune globulin (IVIg)